Refine by
Drug Designation Suppliers & Manufacturers
81 companies found
based inNew York, NEW YORK (USA)
ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers restore ICAM-1 expression which ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
based inHaifa, ISRAEL
Pluristem Therapeutics Inc. is a clinical-stage regenerative medicine company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, muscle injuries, ...
Acute Radiation Syndrome (ARS) involves severe, potentially lethal damage to the bone marrow’s ability to produce blood cells, as well as to other systems and organs. Severe damage to bone marrow makes victims vulnerable to life-threatening ...
based inBasel, SWITZERLAND
EsoCap’s vision is to improve the lives of patients affected by esophageal diseases. The esophagus is a particularly challenging environment, as swallowed drugs only remain in the area between the mouth and the stomach for a few seconds. EsoCap, a ...
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
based inSchlieren, SWITZERLAND
We are an innovative, Swiss life-science Company aiming to provide patients that suffer from large and deep skin defects with the first automate-produced, personalized skin tissue therapy, denovoSkin“ a safe, effective and accessible therapy for ...
To bio-engineer denovoSkin™, a small biopsy of healthy skin is harvested from the patient. The biopsy is processed to isolate epidermal and dermal cells. The cells are expanded in vitro, and thereafter used in combination with a hydrogel to ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inSan Diego, CALIFORNIA (USA)
Capricor is Developing Transformative Cell and Exosome-based Therapeutics for the Treatment and Prevention of Diseases. Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and ...
Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since ...
based in, NETHERLANDS
At veriNOS Pharmaceuticals, we focus on the clinical development of a drug that specifically inhibits a defined cascade that is relevant and common in different disease settings. The activation of iNOS with subsequent excessive production of cell ...
based inOceanside, CALIFORNIA (USA)
Eidogen-Sertanty is dedicated to improving health, medicine, and general well-being. For the last 20-years, Eidogen-Sertanty has helped to expedite the discovery and development of many new, safer medicines through collaborative project team ...
based inSan Carlos, CALIFORNIA (USA)
Alkahest is a clinical stage biopharmaceutical company targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and ...
One the key chronokine targets identified using Alkahest’s platform is eotaxin. Eotaxin is an immunomodulatory chemokine that is increased in normal aging as well as multiple diseases of aging. It has been implicated in Alzheimer’s ...
based inBozeman, MONTANA (USA)
Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections. Microbion is dedicated to developing ...
Cystic Fibrosis (CF) lung disease, which is estimated to affect more than 30,000 in the US and 70,000 worldwide1, is characterized by chronic bacterial infection and severe inflammation that leads to progressive deterioration in lung function. ...
based inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
NHIE is acute or sub-acute brain injury due to asphyxia caused during birth resulting from deprivation of oxygen during birth (hypoxia) as a result of a sentinel event such as ruptured placenta, parental shock and even increased heart rate. Hypoxic ...
based inCambridgeshire, UNITED KINGDOM
Computational, medicinal and synthetic chemists from the world’s leading research organizations use our software on a daily basis. Our customers include 8 out of the top 10 pharmaceutical companies. Beyond pharmaceuticals you will find Cresset ...
A single platform for ligand-based and structure-based drug design that enables research chemists to discover novel small molecules more efficiently and ...
based inSan Francisco, CALIFORNIA (USA)
The invenious platform aims to enhance safety, efficacy, sterility, value and convenience. BioQ designs ready-to-use delivery systems for hard to prepare and hard to administer infusible drugs – thereby simplifying the infusion process from ...
based inWellesley Hills, MASSACHUSETTS (USA)
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 50 countries, TargetMol has evolved into one of ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as ...
based inGeneva, SWITZERLAND
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric ...
Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the ...
based inNanjing, CHINA
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D process and commercial production. Its core businesses include a rationally designed building ...
Virtual screening is a computational approach used to search libraries of small molecules in order to identify hit and even lead compounds. Because of its significantly lower cost, shorter turnaround time, and particularly access to libraries with ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
Our lead product candidate, Trans sodium crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and ...
based inStockholm, SWEDEN
IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. IBT is currently developing its ...
IBP-9414 for the prevention of necrotizing enterocolitis (NEC) contains the active substance Lactobacillus reuteri, which is a co-evolved human bacterial strain naturally present in breast milk. Lactobacillus reuteri is a live bacteria known to be ...